Author

Arndt Vogel

LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS
LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS

Arndt Vogel  et al.

THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIES PATIENTS WITH ADVERSE CLINICAL OUTCOME FROM IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA
THE SYSTEMIC INFLAMMATORY RESPONSE IDENTIFIES PATIENTS WITH ADVERSE CLINICAL OUTCOME FROM IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA

Arndt Vogel  et al.

Item 1 - 2 / 2
1